HBR SMS BA9

BioFreedom™

POLYMER- & CARRIER-FREE DRUG-COATED CORONARY STENT SYSTEM

Powered by BA9™

Freedom to treat



BIOSENSORS INTERNATIONAL™

AVANT MEDICAL

BioFreedom™ Powered by BA9
POLYMER- & CARRIER-FREE DRUG-COATED CORONARY STENT SYSTEM

Freedom to treat

Meeting the Need of High Bleeding Risk (HBR) Patients

At least 20% of PCI patients are High Bleeding Risk (HBR) where there is a need to avoid prolonged dual antiplatelet therapy (DAPT).[1-9] BioFreedom, as a Drug-Coated Stent (DCS), is safer and more efficacious than BMS in High Bleeding Risk patients.

By directly delivering BA9 - an effective anti-restenotic therapy - without polymer or carrier and becoming a BMS at 28 days, the DAPT regime can be shortened when treating patients with the BioFreedom stent.

High Bleeding Risk (HBR)
Normal Bleeding Risk (NBR)

20%

- Age ≥ 75 yrs[1,2]
- Oral Antiooagulation (OAC) after PCI[3]
- Planned major surgery <12 months[4,5]
- History of bleeding/stroke[5,6]
- Anemia (severe)[7]
- Chronic Kidney Disease (CKD)[1]
- Cancer[1]
- Other (DAPT intolerance, poor adherence, Dengue fever)

DAPT = dual antiplatelet therapy

Balancing the Ischemic & Bleeding Risk for HBR Patients with 1 Month DAPT



Recent meta-analysis[10] indicates that long-term DAPT prevents 1 Stent Thrombosis but increases bleeding by 2.1 events.*

LEADERS FREE

The landmark trial (Prospective, Double Blind Randomised (1:1)) evaluating BioFreedom (DCS) in High Bleeding Risk (HBR) patients with 1 month DAPT

BioFreedom is the only active stent with 1 month DAPT that has demonstrated superior outcomes to BMS[11]

With LEADERS FREE, BioFreedom becomes the standard of care for High Bleeding Risk (HBR) patients[11]

Significantly Safer than BMS[11]

29% Reduction in the Rate of the Composite of Cardiac Death, MI, ST

Primary Safety Endpoint (Composite of Cardiac Death, MI, ST)



Number at Risk

DCS	1221	1146	1105	1081	1045
BMS	1211	1115	1066	1037	1000

390 days chosen for assessing primary endpoint to capture potential events driven by the 360 day follow up contact
Hazard Ratio (HR) 0.71; 95% CI : 0.56 to 0.91; P = 0.005 for superiority
* Relative Risk Reduction

Significantly more Effective than BMS[11]

50% Reduction in the Rate of Restenosis

Primary Efficacy Endpoint (Clinically-Driven TLR)



Number at Risk

DCS	1221	1167	1130	1098	1053
BMS	1211	1131	1072	1034	984

390 days chosen for assessing primary endpoint to capture potential events driven by the 360 day follow up contact
Hazard Ratio (HR) 0.50; 95% CI : 0.37 to 0.69; P<0.001 for superiority
* Relative Risk Reduction

BIOFREEDOM™
POLYMER- & CARRIER-FREE DRUG-COATED CORONARY STENT SYSTEM

Powered by BioAzul

Freedom to treat

Juno Stent Platform

Stent Platform Optimised for Delivery to the Coronary Lesion



Largest Cell Openings & Lowest Longitudinal Stent Deformation of 2nd Generation DES

Trackability

Lower peak force represents better trackability, which allows better navigation of the delivery system through the blood vessels



Pushability

Higher pushability is desired to increase the efficiency of the force exerted by the clinician to move the catheter through blood vessels and advance through tight lesions



* Shares same metal platform and delivery system.

Cell Opening Diameter

Large cell opening diameter is desirable, as it provides better access to side branch for subsequent stents



Longitudinal Compression

Lowest Longitudinal Stent Deformation of 2nd GEN[14]